Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue SUPPL. 1, 2006, Pages

  Croft, Simon L ^a   Engel, Juergen ^b  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^b Zentaris GmbH   (Germany)

Author keywords

Alkyl phosphocholines; Anticancer drug; Antileishmanial; Leishmaniasis; Miltefosine

Indexed keywords

4 AMINOMETHYL 1 [2,3 BIS(DECYLOXY)PROPYL] 4 PHENYLPIPERIDINE; ANTILEISHMANIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; CP 46665 1; EDELFOSINE; ILMOFOSINE; LYSOPHOSPHATIDYLCHOLINE; MILTEFOSINE; PERIFOSINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID DERIVATIVE; SRI 62834; STIBOGLUCONATE SODIUM; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG INDUSTRY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; IN VITRO STUDY; LEISHMANIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; SKIN LEISHMANIASIS; SKIN METASTASIS; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; UNITED KINGDOM; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; DRUG DESIGN; GLYCERYLPHOSPHORYLCHOLINE; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33749330723     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.03.009     Document Type: Article

References (43)

1. Achterberg V., and Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 23 (1987) 117-122
2. Achterberg V., and Gercken G. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 26 (1987) 277-287
3. Adinolfi L.E., and Bonventre P.F. Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,65-1). Am. J. Trop. Med. Hyg. 34 (1985) 270-277
4. Avlonitis N., Lekka E., Detsi A., Koufaki M., Calogeropoulou T., Scoulica E., Siapi E., Kyrikou I., Mavromoustakos T., Tsotinis A., Grdadolnik S.G., and Makriyannis A. Antileishmanial ring-substituted ether phospholipids. J. Med. Chem. 46 (2003) 755-767
5. Benveniste J., Tence M., Varenne P., Bidault J., Boullet C., and Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine. C. R. Seances Acad. Sci. D 289 (1979) 1037-1040
6. Bourass J., Loiseau P.M., Bories C., and Letourneux Y. Antileishmanial activity of rac-1-dodecyl-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro. Ann. Trop. Med. Parasitol. 90 (1996) 559-561
7. Brachwitz H., and Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol. Ther. 66 (1995) 39-82
8. Braquet P., and Godfroid J.J. PAF-acether specific binding sites: 2. Design of specific antagonists. Trends Pharmacol. Sci. 7 (1986) 397-403
9. ®) for the treatment of cutaneous breast cancer. Drugs Today 30 (1994) 59-72
10. Croft S.L., Neal R.A., Pendergast W., and Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36 (1987) 2633-2636
11. Croft S.L., Neal R.A., Thornton E.A., and Herrmann D.B. Antileishmanial activity of the ether phospholipid ilmofosine. Trans. R. Soc. Trop. Med. Hyg. 87 (1993) 217-219
12. Croft S.L., Snowdon D., and Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38 (1996) 1041-1047
13. Croft S.L., and Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8 (2002) 319-342
14. Demopoulos C.A., Pinckard R.N., and Hanahan D.J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 254 (1979) 9355-9358
15. Dive G., Godfroid J.J., Lamotte-Brasseur J., Patt J.P., Heymans F., Dupont L., and Braquet P. PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists. J. Lipid. Mediat. 1 (1989) 201-215
16. Eibl H., and Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 17 (1990) 233-242
17. Engel J. Miltefosine, the story of a successful partnership: disease endemic country - TDR - pharmaceutical industry (Zentaris). TDR News 68 (2002) 5
18. 3 (edelfosine) and amphotericin B. Acta Trop. 81 (2002) 151-157
19. Escobar P., Yardley V., and Croft S.L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45 (2001) 1872-1875
20. Ganguly N.K. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News 68 (2002) 2
21. Giantonio B.J., Derry C., McAleer C., McPhillips J.J., and O'Dwyer P.J. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin. Cancer Res. 15 (2004) 1282-1288
22. Godfroid J.J., and Braquet P. PAF-acether specific binding sites: 1. quantitative SAR study of PAF-acether isosters. Trends Pharmacol. Sci. 7 (1986) 368-373
23. Godfroid J.J., Dive G., Lamotte-Brasseur J., Batt J.P., and Heymans F. PAF receptor structure: A hypothesis. Lipids 26 (1991) 1162-1166
24. Herrmann H.O., and Gercken G. Metabolism of 1-O-[1′-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond. Mol. Biochem. Parasitol. 5 (1982) 65-76
25. Hilgard P., Stekar J., Voegeli R., Engel J., Schumacher W., Eibl H., Unger C., and Berger M.R. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur. J. Clin. Oncol. 24 (1988) 1457-1467
26. Hilgard P., Klenner T., Stekar J., Nössner G., Kutscher B., and Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumor activity. Eur. J. Cancer 33 (1997) 442-446
27. Kuhlencord A., Maniera T., Eibl H., and Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36 (1992) 1630-1634
28. Lamotte-Brasseur J., Dive G., Lamouri A., Heymans F., and Godfroid J.J. PAF-receptor. III. Conformational and electronic properties of PAF-like agonists and antagonists. Biochim. Biophys. Acta 666 (1991) 230-237
29. Le Fichoux Y., Rousseau D., Ferrua B., Ruette S., Lelievre A., Grousson D., and Kubar J. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob. Agents Chemother. 42 (1998) 654-658
30. Munder P.G., Weltzien H.U., and Modolell M. Lysolecithin analogs: a new class of immunopotentiators. Immunopathology 7 (1977) 411-424
31. Munder P.G., Modolell M., Bausert W., Oettgen H.F., and Westphal O. Alkyl-lysophospholipids in cancer therapy. In: Hersh E.M. (Ed). Augmenting agents in Cancer Therapy (1981), Raven Press, New York 441-458
32. Murray H.W. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44 (2000) 3235-3236
33. Murray H.W., and Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181 (2000) 795-799
34. Perez-Victoria F.J., Gamarro F., Ouellette M., and Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278 (2003) 49965-49971
35. ®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 85-90
36. Seifert K., Matu S., Perez-Victoria F.J., Castanys S., Gamarro F., and Croft S.L. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22 (2003) 380-387
37. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., Hilgard P., and Murray H.W. Trial of miltefosine for visceral leishmaniasis. Lancet 352 (1998) 1821-1823
38. Tsushima S., Yoshioka Y., Tanida S., Nomura H., Nojima S., and Hozumi M. Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem. Pharm. Bull. (Tokyo) 30 (1982) 3260-3270
39. Unger C., Damenz W., Fleer E.A.M., Kim D.J., Breiser A., Hilgard P., Engel J., Nagel G.A., and Eibl H. Hexadecylphosphocholine, a new etherlipid analogue: studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 28 (1989) 213-217
40. Unger C., Maniera T., Kaufmann-Kolle P., and Eibl H. In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 34 Suppl. F (1998) 133-140
41. Urbina J.A. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 100 Suppl. 1 (2006)
42. Westphal O. Ether lipids in oncology - welcoming address. Lipids 22 (1987) 787-788
43. Yardley V., Croft S.L., de Doncker S., Dujardin J.-C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., and Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73 (2005) 272-275